Our Bureau, New Delhi Friday, May 3, 2024, 15:45 Hrs [IST] Ajanta Pharma has posted a growth of 65 per cent in net profit on a ...

Ajanta Pharma Ltd saw its shares rallying 13 per cent in Friday's trade following its March quarter (Q4) results and the ...

Ajanta Pharma, a specialty pharmaceutical formulation company, witnessed a 13.70% surge in its shares during morning trade ...

Friday's gains come after the company's board approved the buyback of its shares and reported its March quarter earnings. This is the fourth buyback of equity shares for Ajanta Pharma since 2020.

The company anticipates the fastest growth to come from its dermatology portfolio, followed by ophthalmology and cardiology.

Ajanta Pharma recorded a 66 per cent on year spike in consolidated net profit to ₹202.72 crore for the January-March period.

Ajanta Pharma on Thursday said its consolidated net profit increased 66 per cent to Rs 203 crore in the March quarter, aided ...

The board has fixed May 30 as the record date to determine the entitlement and names of shareholders, who will be entitled to participate in the proposed offer for buyback.

Motilal Oswal is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 2,565 in its research report dated May 02, 2024.

Ajanta Pharma on Thursday announced a Rs 285 crore buyback of up to 10.28 lakh shares through a tender offer at a price of Rs ...

Revenue from operations rose to Rs 1,054 crore in the fourth quarter of FY24 as compared with Rs 882 crore in the year-ago ...

The major stocks that hit a 52-week high on the NSE include Ajanta Pharma (10.51%), Arrow Green (8.28%), Max Estates (5.37%), ...